TABLE 4.
Planktonic and biofilm-growing bacteria antimicrobial activity among EB and NFGNBa
| Antimicrobial | EB (18) |
NFGNB (8) |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC |
MBC |
MBIC |
MBEC |
MIC |
MBC |
MBIC |
MBEC |
|||||||||
| S | R | S | R | S | R | S | R | S | R | S | R | S | R | S | R | |
| AMK | 33 (87%) | 5 (13%) | 21 (55%) | 17 (45%) | 30 (79%) | 8 (21%) | 0 | 38 (100%) | 6 (75%) | 2 (25%) | 6 (75%) | 2 (25%) | 5 (63%) | 3 (37%) | 0 | 8 (100%) |
| CRO | 25 (65%) | 13 (35%) | 19 (50%) | 19 (50%) | 20 (53%) | 18 (47%) | 0 | 38 (100%) | NT | NT | NT | NT | NT | NT | NT | NT |
| CAZ | 26 (67%) | 12 (33%) | 21 (55%) | 17 (45%) | 22 (58%) | 16 (42%) | 0 | 100 (100%) | 8 (100%) | 0 (0%) | 7 (88%) | 1 (12%) | 2 (25%) | 6 (75%) | 0 | 100 (100%) |
| CIP | 20 (53%) | 18 (47%) | 17 (45%) | 21 (55%) | 17 (45%) | 21 (55%) | 0 | 100 (100%) | 5 (63%) | 3 (37%) | 3 (37%) | 5 (63%) | 5 (63%) | 3 (37%) | 0 | 100 (100%) |
| CO | 19 (50%) | 19 (50%) | 17 (45%) | 21 (55%) | 13 (35%) | 25 (65%) | 0 (0%) | 100 (100%) | 8 (100%) | 0 (0%) | 7 (88%) | 1 (12%) | 2 (25%) | 6 (75%) | 0 (0%) | 100 (100%) |
| GE | 21 (55%) | 17 (45%) | 9 (24%) | 29 (76%) | 20 (53%) | 18 (47%) | 0 (0%) | 100 (100%) | 6 (75%) | 2 (25%) | 4 (50%) | 4 (50%) | 4 (50%) | 4 (50%) | 0 (0%) | 100 (100%) |
| MP | 36 (95%) | 2 (5%) | 36 (95%) | 2 (5%) | 35 (92%) | 3 (8%) | 0 (0%) | 100 (100%) | 6 (75%) | 2 (25%) | 6 (75%) | 2 (25%) | 5 (63%) | 3 (37%) | 0 (0%) | 100 (100%) |
a
The table shows planktonic (MIC and minimal bactericidal concentration [MBC]) and biofilm-growing bacteria (minimal biofilm inhibitory concentration [MBIC] and minimal biofilm eradication concentration [MBEC]) antimicrobial activity among Enterobacteriaceae (EB) and nonfermenting Gram-negative bacilli (NFGNB). AMK, amikacin; CRO, ceftriaxone; CAZ, ceftazidime; CIP, ciprofloxacin; GE, gentamicin; CO, colistin; MP, meropenem; NT, not tested; R, resistant; S, sensitive.